Press release
Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan Insights
Atopic Dermatitis Market
Latest Japan‐Related News
Japan's top eczema app "Atopiyo" expands to the US - the app, developed in Japan, is now internationally available
Dupixent (dupilumab) receives approval in Japan for treating atopic dermatitis and other conditions
Maruho to co-develop topical biologic B244 in Japan through a licensing deal with AOBiome
Tapinarof cream (Vtama) approved in Japan for atopic dermatitis in patients 12+
Unlock exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://datamintelligence.com/download-sample/atopic-dermatitis-market?kb
Recent Industry Trends (2025)
Gilead and LEO Pharma Collaboration (Jan 2025): A strategic partnership was formed to advance the STAT6-targeted oral small molecule program aimed at treating inflammatory skin disorders, including atopic dermatitis.
Eli Lilly Acquires Dice Therapeutics (Mar 2025): This acquisition strengthens Lilly's dermatology pipeline by incorporating oral IL-17 inhibitors, expanding therapeutic options for atopic dermatitis (AD).
AI-Powered Dermatology Tools: Artificial intelligence-based skin scanners have been integrated into dermatology applications, enabling real-time skin health monitoring. These tools are increasingly being used in both U.S. and Japanese clinics.
Decentralized Clinical Trials: The adoption of virtual and remote clinical trials continues to grow in 2025. This approach has improved patient recruitment and retention in AD trials by offering virtual consultations and remote monitoring.
Atopic Dermatitis Market Overview
The Atopic Dermatitis encompasses the global industry focused on the diagnosis, treatment, and management of atopic dermatitis (also known as eczema)-a chronic inflammatory skin condition characterized by dry, itchy, red, and inflamed skin. This market includes topical treatments, systemic drugs (like biologics and JAK inhibitors), and emerging digital health solutions
Research Methodology:
The global Atopic Dermatitis Market research report is based on a combination of primary and secondary data sources. The study carefully analyzes various factors influencing the industry, including government regulations, market dynamics, competitive landscape, historical trends, current conditions, and technological progress. It also evaluates future developments, related industry trends, market volatility, growth prospects, potential obstacles, and emerging challenges.
Segment Covered in the Atopic Dermatitis Market:
By Treatment Type: Corticosteroids, Hydrocortisone, Mometasone, Betamethasone, Prednisone, Others , Immunosuppressants , Calcineurin Inhibitors , Cyclosporine, Tacrolimus, Pimecrolimus, Others , JAK Inhibitors , Abrocitinib, Upadacitinib, Others , PDE-4 Inhibitors , Others , Biologics , Dupilumab , Tralokinumab, Others, Antihistamines, Others , , By Patient Type, Children, Adults
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/atopic-dermatitis-market?kb
List of the Key Players in the Atopic Dermatitis Market:
Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Galderma Inc., LEO Pharma Inc., Incyte Corporation, Arcutis Biotherapeutics, Inc., Otsuka Pharmaceutical Co., Ltd, and others.
Atopic Dermatitis Market Emerging Players
The emerging players in the atopic dermatitis market include Almirall, S.A, Aclaris Therapeutics Inc, Kiniksa Pharmaceuticals, Cara Therapeutics, VYNE Therapeutic and among others.
Key Developments in the Atopic Dermatitis Market
April 2025 - Galderma's DTC Campaign: Galderma launched "Scratch Resistance," its first multichannel direct-to-consumer campaign for NEMLUVIO (nemolizumab-ilto). The initiative emphasizes the broader emotional and lifestyle challenges of living with atopic dermatitis, beyond the physical itch.
March 2025 - Amgen & Kyowa Kirin: New insights emerged from the ROCKET Phase 3 trial of rocatinlimab, a therapy that targets the OX40 receptor to rebalance T-cell activity in moderate-to-severe AD patients.
January 2025 - FDA Approves Nemluvio: The U.S. FDA approved Nemluvio (nemolizumab-ilto), a novel IL-31 inhibitor by Galderma, for adolescents and adults with moderate-to-severe atopic dermatitis who are unresponsive to topical therapies.
September 2024 - EBGLYSS Approval: Eli Lilly received FDA approval for EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor designed to treat patients aged 12 and older with moderate-to-severe AD not controlled by topical prescriptions.
April 2024 - Dermavant's VTAMA sNDA: Dermavant announced FDA acceptance of its supplemental NDA for VTAMA (tapinarof) cream, 1%, targeting AD in patients aged 2 and older. A final decision is expected by Q4 2024.
July 2024 - ZORYVE Cream Approval: Arcutis Biotherapeutics secured FDA approval for its sNDA for ZORYVE (roflumilast) cream, 0.15%, offering a non-steroidal treatment for mild-to-moderate AD in patients aged 6 and above. The cream delivers fast relief and supports long-term disease management.
Regional Analysis for Atopic Dermatitis Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
The Report Includes:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.
People Also Ask:
➠ What are the global sales, production, consumption, imports, and exports in the Atopic Dermatitis market?
➠ Who are the top manufacturers, and what are their capacity, production, sales, pricing, and revenue stats?
➠ What key opportunities and challenges do vendors face in the Atopic Dermatitis industry?
➠ Which product types, applications, or end-users are driving market growth, and what is their market share?
➠ What are the major growth drivers and restraints of the Atopic Dermatitis market?
Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Market Overview 2025 and Growth US$ 31.68 Bn by 2033 | Japan Insights here
News-ID: 4076725 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Induction Motor Market 2031 | Growth Drivers, Trends & Market Fore …
Induction Motor Market size was worth US$ 20.36 billion in 2023 and is estimated to reach US$ 33.66 billion by 2031, growing at a CAGR of 6.49% during the forecast period (2024-2031).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/induction-motor-market?kb
List of Top Key Player:
ABB Ltd., Ametek, Emerson Electric, Siemens AG, Brook Crompton, Danaher Corporation, Johnson Electric Holdings, Regal Beloit, WEG Electric Corp.…
Digital Therapeutics Market Set for Explosive Growth to USD 39.52 Billion by 203 …
The Global Digital Therapeutics Market size reached USD 6.84 billion in 2024 and is expected to reach USD 39.52 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033.
Market growth is driven by the rising prevalence of chronic diseases like diabetes and mental health disorders, increasing smartphone penetration, and growing patient demand for personalized, app-based interventions. Advancements in AI and machine learning for behavior change, expanding…
United States Contrast Media Injectors Market: Real-Time Market Trends & Competi …
DataM Intelligence unveils its latest report on the "Contrast Media Injectors Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies…
United States Real Time Location System (RTLS) Market Analysis 2026: Growth Driv …
Real Time Location System (RTLS) Market is expected to grow at a CAGR of 18% during the forecasting period (2022-2029).
Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://www.datamintelligence.com/download-sample/real-time-location-system-market?kb
United States: Recent Industry Developments
✅ December 2025: Major healthcare systems expanded RTLS deployments to enhance patient tracking, asset utilization, and workflow efficiency.
✅ November 2025: Leading tech providers integrated AI‐driven analytics into RTLS platforms to deliver predictive…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
